Yuviwel (navepegritide / TransCon CNP) PDUFA Date (Ascendis Pharma)
FDA PDUFA decision date for Yuviwel (navepegritide / TransCon CNP) is February 28, 2026. Developed by Ascendis Pharma. Indication: Achondroplasia (pediatric). Current status: Approved.
Indication
Achondroplasia (pediatric)
Regulatory details
- Company: Ascendis Pharma
- Therapeutic area: Rare Disease / Bone
- Application type: NDA
- Review type: Priority
- PDUFA date: 2026-02-28
- Outcome: Approved